ZC TECH GP(08511.HK)一季度虧損擴大至210萬港元
格隆匯8月9日丨ZC TECH GP(08511.HK)宣佈,截至2021年6月30日止3個月,公司未經審核收益約660萬港元,較去年同期增加約161.1%;公司擁有人應占未經審核虧損為210萬港元,去年同期虧損為200萬港元,主要歸因於毛利減少。
精密3D檢測解決方案:精密3D檢測解決方案的收益由截至2020年6月30日止三個月的250萬港元增加161.1%至截至2021年6月30日止三個月的660萬港元。該增加乃主要由於集團執行的精密3D檢測解決方案項目的合約價值增加所致。截至2021年6月30日止三個月,公司新增一份約450萬港元的銷售合約。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.